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Abstract: Nonadherence in children who use long-term medication is a serious problem and
assessing adherence is an important step to provide solutions to this problem. Medication
adherence can be measured by several methods, including (a) self-report questionnaires or
structured interviews, (b) therapeutic drug monitoring (TDM), (c) electronic devices, and (d)
pick-up/reﬁll rates. The objective of this narrative review is to provide an overview of the
literature about methods for the measurement of medication adherence in chronically ill
children and adolescents. Therefore, we conducted a literature search by using multiple
databases. Four methods of monitoring medication adherence are presented for the most
described chronic diseases: asthma, HIV/AIDS, epilepsy, diabetes mellitus and ADHD. First,
10 commonly used self-report questionnaires and structured interviews are described, including
the main characteristics, (dis)advantages and their validation studies. Second, the use of TDM
in pediatric trials for medication adherence measurement is discussed. New sampling methods
(e.g. dried blood spot) and sampling matrices (e.g. hair, saliva and urine) have shown their
beneﬁts for TDM in children. Third, electronic devices to measure medication adherence in
children are presented, being developed for several drug administration routes. Fourth, the
analyses, advantages and disadvantages of pharmacy data are discussed. The usage of this data
requires speciﬁc calculations and interpretations to assess adherence. As presented in this
review, every adherence method has speciﬁc (dis)advantages. When deciding which adherence
method is applicable, validity and generalizability should be taken into account. Combining
multiple methods seems to offer the best solution in the daily clinical practice.
Keywords: adherence, children, chronic illness, measurement, medication, (general) pediatrics
Introduction
With a prevalence of 26.6% and rising among children in 2006, chronic diseases are
a main contributor to both morbidity and mortality.1,2 Pharmacological therapy is
often essential for the treatment of these chronic diseases to prevent further
deterioration.3 However, for effective pharmacological treatment, medication adher-
ence is of great importance. Medication adherence is suggested to be even more
important in the pediatric population.4 Moreover, medication adherence in children
with chronic illnesses is more complex than adherence in adult populations. Several
causes might contribute, including the lack of physical capacity or cognitive under-
standing which impedes self-administration by children. Also, child resistance is
not uncommon, especially in the case of aversive formulations and time-consuming
medical therapies. Cultural beliefs of parents and caregivers about treatments, the
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role of family size and parental marital status are examples
of other contributing factors to pediatric adherence.5,6
These factors highlight a complex inﬂuence on mea-
suring medication adherence in minors, caused by the
children’s (mainly infants and toddlers) dependency on
parents and caregivers. As such, two extra elements are
added to the (usual) therapeutic relationship between med-
ical professionals and the patient: communicative interac-
tions between parent and child, and between parent and
professionals. This leads to a “therapeutic triad partner-
ship” in pediatric care.5–7
Medication nonadherence can have serious conse-
quences, including failure of therapy. The speciﬁc conse-
quences of failure of therapy logically depend on the
prescribed pharmacological treatment. For example, non-
adherence of methylphenidate may cause less attention
and more hyperactivity, and thus decreased cognitive
performance.8 However, nonadherence of antiretroviral
therapy can have possible life-threatening consequences
as it predicts virologic suppression among HIV-positive
patients.9 Besides failure of therapy, nonadherence can
also lead to toxicity and pharmacological interactions. In
this way, medication nonadherence might increase morbid-
ity and mortality, and negatively impact the health-care
costs.10–13
Despite the importance of medication adherence, non-
adherence is very common among children and adolescents.
Only 58% medication adherence has previously been
reported in children who use long-term medication.13
Therefore, monitoring of medication adherence is of great
importance.
Several different approaches to monitor medication
adherence have been developed. These include (a) self-
report questionnaires or structured interviews, (b) thera-
peutic drug monitoring (TDM), (c) electronic devices and
(d) pharmacy pick-up/reﬁll rates.14,15 TDM refers to the
measurement of drugs in the patient’s body ﬂuids, often in
the bloodstream, with the aim of optimizing individual
dosage regimens.16 Pick-up and reﬁll rates include phar-
macy-dispensing records to assess adherence.14
Unfortunately, no complete overview of options for
drug adherence in children and adolescents is currently
available. Previously published reviews did not discuss
TDM or focus solely on questionnaires in this
population.17,18 Other reviews tend to focus only on spe-
ciﬁc disorders and/or therapies, for example, asthma.19
Therefore the objective of this narrative review is to
provide a comprehensive overview of the literature
concerning measuring methods of medication adherence
in chronically ill children. This review focuses on the
usage of these methods in the daily clinical practice, with
a special focus on the ﬁve most common chronic condi-
tions which our search retrieved: asthma, HIV/AIDS, epi-
lepsy, diabetes mellitus, and attention deﬁcit hyperactivity
disorder (ADHD). The outcomes of this review mainly
concern an overview of the strengths and weaknesses of
the medication adherence assessment methods, along with
a description of recent developments.
Methods
We conducted a literature search in the following data-
bases: Embase.com, Medline Ovid (PubMed), Web of
Science, Cochrane Central and Google Scholar. The search
terms and their corresponding synonyms used were: adher-
ence, assessment, drug therapy, questionnaires, TDM,
electronic devices, pick-up/reﬁll rates, and children/ado-
lescents. These search strategies did not contain any
restrictions in time frame or in the type of study.
Studies that primarily focused on medication adherence
measurement methods in children and adolescents with
chronic diseases (i.e. with medication used for at least
one month), were selected. Additional articles were also
selected by screening the references of included articles.
For the statistical tests that were used for the validation
of questionnaires, P-values less than 0.05 have been con-
sistently considered as signiﬁcant.
Results
The ﬁve most prominent diseases with the most retrieved
articles and which have been described the most in litera-
ture are presented: asthma, HIV/AIDS, epilepsy, diabetes
mellitus and ADHD. The largest amount of articles men-
tioned the use of (speciﬁc) questionnaires and the fewest
number of articles described pick-up and reﬁll rates as
a method to measure medication adherence in children.
Questionnaires and structured interviews
Self-report questionnaires are considered a convenient,
indirect and efﬁcient method to measure adherence among
patients. The biggest advantages of using questionnaires are
their easy applicability in the clinical practice and low
cost.20 However, questionnaires might be subject to recall
and response bias which might decrease their accuracy and
validity. Furthermore, due to the patients fear of disappoint-
ing doctors, results of questionnaires might lead to an over-
estimation of the level of adherence.21
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In total, our search retrieved 10 validated and well-
described questionnaires, which are listed in Table 1.
Structured interviews have been included as well.
Additional speciﬁcations of these questionnaires, such as
the number of questions, validation and (dis)advantages
are presented in Table 2. Methodological limitations of the
concerning studies next to restrictions of the question-
naires are also presented in Table 2.
As can be seen, the questionnaires have been devel-
oped both for parents and for children. Furthermore, the
questionnaires and structured interviews have been vali-
dated in different research populations, using various out-
come measures. It is remarkable that the validation
processes of the questionnaires and structured interviews
have been performed in various manners.
A general questionnaire, which can be applied to dif-
ferent chronic diseases, is the “Chronic Disease
Compliance Instrument” (CDCI). It was tested in diabetics
ﬁrst, but later adjusted to an English version and made
available in patients (mainly adolescents) with rheumatoid
arthritis, asthma and epilepsy. The development of this
instrument and the associated different phases have been
described extensively by Kyngäs et al.22 The CDCI can be
used both for clinical and research purposes and—depend-
ing on the version—the compliance item has a Cronbach’s
α value (correlation coefﬁcient) ranging from 0.78 to 0.86.
Therapeutic drug monitoring
TDM comprises measurement of drug concentrations in
body ﬂuids, often serum and plasma, of an individual
patient. TDM is more often used as a tailored drug man-
agement tool to adjust doses in the optimal target range,
than as a method to monitor drug adherence.23 However,
TDM is the only direct objective measure of medication
adherence and has thus been used for this purpose in
scientiﬁc research, for example, in the therapeutic manage-
ment of HIV-infected children.24
Unfortunately, clinical research on TDM in children
has been an underdeveloped area. Data and reference
values on TDM in children are limited.25 Results from
adult pharmacokinetic studies cannot be simply extrapo-
lated to children, as physiological and biochemical differ-
ences lead to different pharmacokinetics and, thus,
interpretation of drug concentrations.26
However, for some agents a clear pharmacokinetic proﬁle
in children is known. For certain anti-epileptic drugs (AEDs),
TDM is a reliable tool for clinicians in order to optimize drug
dosing in children and measure adherence.27
An important disadvantage of TDM is its invasive
method of sampling. Children especially might experience
a high level of anxiety when a venepuncture is
conducted.28 Therefore, less invasive and more convenient
methods of sample collection have been explored for this
population. A range of these alternative sampling methods
may serve as a solution for the difﬁculties encountered in
the implementation of TDM in pediatric populations, as
they might be less invasive compared to the conventional
venepuncture.
Firstly, the dried blood spot (DBS) is a method which
uses a simple prick in the ﬁnger, toe or heel for the collection
of one drop of blood on a ﬁlter paper. DBS was initially
developed as a screening method for metabolic defects in
newborns, and is now being applied for TDM for a wide
spectrum of drugs.29 A main advantage of this method is that
less blood volume is needed, thus reducing the risk of trans-
ferring infections and pathogens.29 Moreover, its applicabil-
ity in the home setting makes the DBS a convenient and
ﬂexible tool to collect blood, which leads to a reduction in the
total costs as well.30
Secondly, samples of other matrices have also been used
for the assessment of adherence, including, saliva, scalp
hair, tears, and urine.23 Saliva is described as a suitable
matrix to measure asthma medication and anticonvulsants.
However, saliva is not a good representation of the plasma
concentration for all anticonvulsants, e.g. valproic acid (or
valproate sodium) and phenobarbital.31–33 For hair, a more
recent study (Prasitsuebsai et al) showed the association
between antiviral drug concentrations (lopinavir/ritonavir
regimens) in hair and virologic outcomes, while adherence
measured by self-reports, drug plasma levels and pill counts
did not show an association with virological success.34 The
main advantage of hair sampling, beside its easiness, is the
detection of longer-term compliance in HIV-infected
children.34 Interestingly, Guillet et al have used the collec-
tion of urine samples to detect the presence of phenobarbital
in neonates.35 However, more research on the relationship
in other populations, e.g. older children and children with
decreased renal function, is needed.35
Although it is beyond the scope of TDM, sputum
eosinophil count has been described as a guidance to
assess compliance in patients using corticosteroid treat-
ment to control their asthma as well.36 Also, the simpler
measurements of increased exhaled nitric oxide (FeNO)
levels have been found to be related to lower rates of
medication adherence and, therefore, serve as a useful
clinical tool.37,38
Dovepress Al-Hassany et al
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Electronic medication monitoring
With technological improvements made in health care since
the early 1990s, the invention of electronic monitors to
assess adherence has been a valuable addition to the exist-
ing pediatric adherence measurement methods. Electronic
adherence measurement devices have been even regarded as
the “gold standard” of adherence measurement.39,40
General systems
Ingerski et al have provided an extensive overview of elec-
tronic monitors, separated for each illness group in pediatric
populations.41 As mentioned by Ingerski et al, electronic
monitors can be categorized into three main groups: the
oral medication monitors, the inhaled medication monitors,
and the nebulized medication monitors.41
Oral medication monitors consist of the electronic drug
exposure monitor (eDEM) or the similar, but newer and
well-known device medication event monitoring system
(MEMS®; Aardex Group, Seraing, Belgium). It consists
of a computer chip in the bottle cap, which records the
date and time each time the pill bottle is opened.41,42
Moreover, MedSignals®(MedSignals/VitalSignals LLC,
Lexington, KY, USA) is an electronic pill box which
aids in the management of medication intake by providing
real-time feedback on the patients adherence.41
Examples of inhaled medication monitors consist of
the DOSER (MediTrack Products LLC, South
Easton, MA, USA), Medtrack metered-dose inhaler
(MDI) Chronolog, MDILog (Westmed, Inc., Tucson,
AZ, USA) and the Smartinhaler Tracker (Adherium
Ltd, Auckland, New Zealand). Moreover, a couple of
monitors have been described which measure nebu-
lized medication: I-neb adaptive aerosol delivery
(AAD) or the HaloLite nebulizer (Respironics,
Chichester, UK/Respironics Respiratory Drug
Delivery, Cedar Grove, NJ, USA) and the Nebulizer
Chronolog (Forefront Technologies Inc, Lakewood,
CO, USA), for example.41
New systems
An important and more recent development is the real-
time medication monitoring (RTMM) system, which reg-
isters the number of inhaled corticosteroids for example.
By connecting this system to a pressurised metered-dose
inhaler (pMDI), time and the date of the given (inhaled)
doses can be measured. The collection of the obtained data
occurs by sending them to a study database through
a mobile telephone network.43,44
The real-time wireless electronic adherence monitor
(EAM) has been described in a HIV-infected population
as well. Haberer et al have mentioned this way of mon-
itoring as a feasible and a valid method—considering the
opportunity it offers to intervene with adherence chal-
lenges directly, although it does have its technical and
cost-related difﬁculties.45
Lastly, the multifunctionality of electronic mobile
devices (smartphones) has been shown to be useful in
the measurement and improvement of adherence in the
short-term. Reminder systems, for example, short message
service (SMS) text messages, can be synced with monitor-
ing devices. Synchronization of these smartphones might
also facilitate transmission of data from monitoring
devices to patients or physicians.46,47
Primary advantages and disadvantages
Next to the noninvasive measurement of adherence, elec-
tronic monitors could serve other purposes, including help-
ing the patient to handle complex dosing regimens and
dose timings.41 An extra advantage in pediatric popula-
tions is the possibility to divide responsibilities of medica-
tion dispersion within families. However, they often do not
monitor the actual ingestion of medications, have a chance
of missing data, and due to their high costs, they are not
routinely being used in the clinical setting.48
Unfortunately, although validated in adult studies, data
about the validation and reliability of these devices in
a pediatric population has not always been provided.41
Pick-up and reﬁll rates
Pharmacy data may serve as a source for the calculation of
pick-up rates and reﬁll rates. Pick-up rates describe the
number of picked-up prescriptions as a percent of the total
prescribed doses.49 Reﬁll rates are deﬁned as the division
of the amount of days the drugs have been prescribed by
the total calendar days of that period.50 Several methods
and approaches exist to estimate the medication reﬁll rate.
Vink et al compared these methods in an observational
cohort study with a relatively old diabetic population
(mean age 66 years).51 Two methods were considered
sensitive methods in case of multiple drug usage: the
medication possession ratio (MPR) using a one-year
ﬁxed period or the maximal gap between reﬁlls (GAP).51
Methodological transparency remains an important fac-
tor in the analyses using pharmacy claims data.52 The
different methods to calculate adherence by using phar-
macy records lead to different adherence rates and should
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therefore be mentioned and taken into account.49
Comparable studies for children have not been found.
As described earlier, the reﬁll rate is deﬁned as the
number of days that a (particular) medicine has been
dispensed to a patient in a deﬁned period, divided by the
total number of days in that time period. Pharmacy records
have shown a good correlation to other compliance mea-
sures, for example, oral and written self-report measures.
Moreover, their calculation is relatively easy and
inexpensive.50,53
However, important limitations of the usage of pick-up
rates are mentioned by Mudd et al.54 Pharmacy records do
not measure actual administration of the medication. For
example, medication may be shared among members of
a household.54 Another limitation is that adjustments of
medication doses by the physician are not always reﬂected
by these rates. Calculations of pick-up rates can thus also
lead to an overestimation of the patient’s nonadherence,
and false-positive results.
When interpreting pharmacy record data, it should be
taken into account that current outcomes are better pre-
dicted than future outcomes. Also, a longer duration of this
adherence assessment (more than six months) has been
found to be more predictive for the future outcome.55
Our search retrieved different sources to collect these
pharmacy data. A difference can be made, for example,
between Medicaid pharmacy data and data collected from
individual pharmacies (also called “pharmacy record
data”), which have been compared by Mudd et al.56
Most retrieved articles used adults as their research popu-
lation and did not validate their method speciﬁcally in
a chronically ill pediatric population.
Discussion
By performing a broad literature search using several
databases, we provide an overview of the four main adher-
ence measurement methods in chronically ill children:
questionnaires and structured interviews, TDM, electronic
devices and pick-up and reﬁll rates. To provide helpful
tools in measuring adherence in the clinical setting, we
have focused on ﬁve main diseases among children.
In total, we have selected ten validated questionnaires
for ﬁve chronic diseases. For most of the questionnaires,
parents of caregivers are the assessor. Especially in chroni-
cally ill children, caregivers play an important role in the
administration of medication. Therefore, the creation and
usage of questionnaires which allow parents to say how
they feel about medication usage without being judged or
criticized, is highly important. An example of such
a questionnaire is the Pediatric Inhaler Adherence
Questionnaire (PIAQ).57 An indirect inquiry may be
more effective to minimize socially desired, and thus
biased behaviour, and eventual miscommunication.58
A large amount of the found articles reported question-
naires and interviews which were not reusable to assess
adherence, as their validity was unknown. This makes it
impossible to evaluate these instruments. Furthermore, for
the questionnaires that have been validated, the validation
methods varied, making comparisons difﬁcult. Crohnbach’s
α is an often-used measure for internal consistency and
reliability of questionnaires. A questionnaire with
Crohnbach’s α >0.70 is often considered as having a high
internal consistency.59 Table 2 shows that this measure has
not been provided for all instruments. On the contrary, the
sensitivity, speciﬁcity, positive predictive values (which are
not intrinsic to the questionnaire) and intraclass correlations
(instead of the Pearson correlation coefﬁcient) have been
mentioned more commonly.60 Moreover, the duration of the
validation studies differed remarkably. Also, a great varia-
tion in researched populations was observed, with diverse
cultural and linguistic backgrounds. Several studies have
described lower medication adherence rates in people with
culturally and linguistically diverse backgrounds.44,61,62 We
advise more unambiguity herein. Besides the statistical
method, study population and duration of the validation
study, the comparator should also be taken into account.
With regards to electronic medication monitoring,
MEMS® are regarded as the golden standard in measuring
adherence. However, not all instruments were pitted against
this standard. Moreover, it can be questioned if this indeed
is the best method available to assess medication
adherence.63 Electronic adherence monitoring devices—
which can be categorized into three main groups: the oral
medication monitors, the inhaled medication monitors and
the nebulized medication monitors—surely have their indi-
vidual technical limitations and mechanical failures.41
Therefore, other methods should be considered as an useful
comparator for medication adherence method validations,
including TDM. New developments in the area of electronic
monitoring include the Real Time Medication Monitoring
(RTMM) system, and the real-time wireless Electronic
Adherence Monitor (EAM), which offers the opportunity
to potentially intervene with adherence challenges, as well
as (the multi-functionality of) smartphones.
TDM might now be an undervalued adherence method,
due to its invasiveness and the lack of knowledge about
Dovepress Al-Hassany et al
Patient Preference and Adherence 2019:13 submit your manuscript | www.dovepress.com
DovePress
1185
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
5.
17
6.
8 
on
 0
4-
Se
p-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
the interpretation. However, TDM is the only direct objec-
tive measure of medication adherence. Moreover, due to
recent developments in new sampling techniques and
matrices like urine and hair, TDM might have become
a very suitable and patient-friendly tool for adherence
measurement in children. Also, this measure might be of
great beneﬁt for patients with mental diseases, for example
schizophrenia, who may suffer from impaired disease
awareness and social isolation, as most of these sample
techniques can be applied at home.64,65 However, the
applicability of these TDM assays is still limited, as
more research about their validity should be performed.
The use of pharmacy records to calculate the pick-up rates
or reﬁll rates, in order to measure compliance, has shown to be
relatively easy and inexpensive. It is striking that this adher-
ence method was the least described method in the retrieved
articles, probably due to the fact that not all pharmacy data-
bases are standardized.17 Furthermore, the calculations should
be interpreted with caution, as they do not show the actual
administration of the prescribed drugs. This an important dis-
advantage of several electronic monitors as well.
Adherencemeasurement is important for outcomes in both,
the clinical setting and the research domain. The choice for the
most suitable adherence tool depends on the setting, the popu-
lation, and validity of the adherence tool. Firstly, for a clinical
setting, easy implementation in clinical routine is essential. For
example, the usage of pharmacy records may be less practical,
as the calculation of pick-up rates is time consuming. For the
research setting, however, this might be less of a problem.
Secondly, the population is of importance, including factors
like age and type of disease. Adolescents with asthmamight be
able to assess their adherence with a questionnaire themselves,
while for adolescents with cognitive disorders or alcohol
addiction for example this is more problematic. Thirdly, the
(external) validity, or the generalizability, is important. This
applies to every adherence method, thus not only for ques-
tionnaires. Moreover, for example for TDM, it should be
assessed what the certainty of non-adherence is when no
drug can be detected in the blood.
As is stated in this review, every adherence measure-
ment tool has its own advantages and disadvantages. The
perfect method to measure medication adherence does not
exist. Therefore, the usage of a combination of tools might
offer the best solution.66 Combining a more subjective
measurement method, for example questionnaires, with
a more objective measurement method, for example TDM,
might strengthen the assessment.67 Also different sources of
information, i.e. children and parents, are of added value.
We recommend the validation of questionnaires, which are
originally validated in adult populations, in children and adoles-
cents as well - for example the Morisky Medication Adherence
Scale. We also encourage different specialisations to learn from
eachother and to look to the applicability of advancementsmade
in different specializations. Adherence measurement is not only
important as non-adherence inﬂuences health outcomes; it also
enables targeted interventions to improvemedication adherence.
Such interventions may include psycho-education or dosage
reminders.68 Lastly, further research is required to examine the
consistency among the different medication adherence methods
and the level of agreement between reports of adherence from
children and parents/caregivers.69,70
A strength, but also a limitation of our review is the broad
scope. It is striking that not all questionnaires, as presented by
Quittner et al, have been found.17 Our broad scope may have
led to the consequence that not all relevant articles have been
included and reviewed. Furthermore, we did not describe lesser
used adherence tools, such as pill counts and home-visiting
nurses, bottle/canister weights and daily diary methods, for
example.17,66,71,72 However, we conducted an extensive search
in multiple databases and focused on different diseases, not
limited to a speciﬁc condition or method. This provides an
important update of earlier reviews on adherence measuring
methods in paediatric populations.
Conclusion
We provide an updated narrative overview of four major
methods to measure adherence in chronically ill children. By
describing recent developments, next to the advantages and
disadvantages, we give clinicians the tools to make a well-
founded decision in choosing the right adherence method(s).
Key points
What is known:
● Medication adherence can be measured by several
methods: self-report questionnaires (structured inter-
views), TDM, electronic devices and pick-up/reﬁll
rates. It is recommended to assess adherence by com-
bining multiple adherence methods, while keeping their
individual (dis)advantages in mind.
What is new:
● To provide a comprehensive and updated narrative
review of the existing literature concerning measurement
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methods of medication adherence in children and ado-
lescents with a chronic illness.
The review focuses on the usage of thesemethods in pediatric
populations with common chronic conditions: asthma, HIV/
AIDS, epilepsy, diabetes mellitus and ADHD. With this over-
view, we aim to provide clinicians the tools to make the right
decisionwhen assessing adherence in the daily clinical practice.
Disclosure
The authors report no conﬂicts of interest in this work.
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